asti schreef op 25 februari 2016 13:24:
[...]
''Finally, we're focused on improving Cologuard by developing ways to optimize its performance and improve margins. We have begun a program to replace Cologuard's NDRG4 biomarker, which is licensed to EXACT Sciences by MDxHealth. We expect this program will take 18 months to 24 months to complete. Royalties for MDxHealth are in the low- to mid-single digits.''
Ze willen bij Exas de biomarker vervangen. Ze zijn al begonnen aan een programma om de biomarker te vervangen.
Improving margins. Zodat ze die royalties niet hoeven te betalen aan MDxHealth dus.